Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Quench Bio, a start-up in Cambridge, Massachusetts, has raised $50 million in series A financing to develop small molecules that target gasdermin D, a protein implicated in inflammatory conditions and activated by inflammasomes. Gasdermin D kills cells by forming rings that poke holes in the cell membrane, causing the cells to burst and release inflammatory molecules. Quench hopes that inhibiting gasdermin D will help treat diseases like rheumatoid arthritis, lupus, multiple sclerosis, and nonalcoholic steatohepatitis.
This article has been sent to the following recipient: